SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
October 30, 2001
Date of Report (Date of earliest event reported)
NEOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware (State or other Jurisdiction of Incorporation) |
000-28782 (Commission File Number) |
93-0979187 (IRS Employer Identification Number) |
| 157 Technology Drive Irvine, California (Address of principal executive offices) |
92618 (Zip Code) |
(949) 788-6700
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
| Item 5. Other Events. | ||||||||
| Item 7. Exhibits | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| Exhibit 99.1 | ||||||||
Item 5. Other Events.
On October 30, 2001, NeoTherapeutics, Inc. issued a news release regarding modifications to the data analysis schedule of the company’s Alzheimer’s disease clinical trial of its lead drug candidate, Neotrofin™, that is currently in progress. The text of the press release is set forth in Exhibit 99.1 attached to this report and incorporated herein by this reference.
Item 7. Exhibits
Exhibits:
| 99.1 | Press Release dated October 30, 2001. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEOTHERAPEUTICS, INC. | ||
| | ||
| Date: October 30, 2001 | By: | /s/ Samuel Gulko |
| Name: | Samuel Gulko | |
| Title: | Senior Vice President, Finance, Chief Financial Officer, Secretary and Treasurer |
|
\
EXHIBIT INDEX
| Exhibit Number |
Document Description | |||
| 99.1 | Press Release dated October 30, 2001. | |||